ANIXA BIOSCIENCES INC (ANIX) Stock Price, Quote, News and Overview
NASDAQ:ANIX - Nasdaq - US03528H1095 - Common Stock - Currency: USD
ANIX Quote, Performance and Key Statistics
3.49
+0.11 (+3.25%)
The current stock price of ANIX is 3.49 USD. In the past month the price increased by 34.23%. In the past year, price increased by 57.92%.
ANIX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.89 | 324.59B | ||
| AMGN | AMGEN INC | 13.12 | 146.49B | ||
| GILD | GILEAD SCIENCES INC | 13.72 | 132.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.55 | 55.27B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.83B | ||
| ARGX | ARGENX SE - ADR | 94.05 | 33.02B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.58 | 27.86B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.76B | ||
| NTRA | NATERA INC | N/A | 23.26B | ||
| INSM | INSMED INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.89 | 18.28B |
Related stock screener links
About ANIX
Company Profile
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. The company is headquartered in San Jose, California and currently employs 5 full-time employees. The firm's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The firm's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The firm is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the α-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
Company Info
ANIXA BIOSCIENCES INC
3150 Almaden Expy Ste 250
San Jose CALIFORNIA 95118 US
CEO: Amit Kumar
Employees: 5
Phone: 14087089808
ANIXA BIOSCIENCES INC / ANIX FAQ
What is the stock price of ANIXA BIOSCIENCES INC today?
The current stock price of ANIX is 3.49 USD. The price increased by 3.25% in the last trading session.
What is the ticker symbol for ANIXA BIOSCIENCES INC stock?
The exchange symbol of ANIXA BIOSCIENCES INC is ANIX and it is listed on the Nasdaq exchange.
On which exchange is ANIX stock listed?
ANIX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ANIXA BIOSCIENCES INC stock?
9 analysts have analysed ANIX and the average price target is 9.18 USD. This implies a price increase of 163.04% is expected in the next year compared to the current price of 3.49. Check the ANIXA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ANIXA BIOSCIENCES INC worth?
ANIXA BIOSCIENCES INC (ANIX) has a market capitalization of 112.38M USD. This makes ANIX a Micro Cap stock.
How many employees does ANIXA BIOSCIENCES INC have?
ANIXA BIOSCIENCES INC (ANIX) currently has 5 employees.
What are the support and resistance levels for ANIXA BIOSCIENCES INC (ANIX) stock?
ANIXA BIOSCIENCES INC (ANIX) has a support level at 3.33 and a resistance level at 3.74. Check the full technical report for a detailed analysis of ANIX support and resistance levels.
Should I buy ANIXA BIOSCIENCES INC (ANIX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANIX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANIX, evaluating the profitability, health, valuation and growth aspects
- ANIXA BIOSCIENCES INC (ANIX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ANIXA BIOSCIENCES INC (ANIX) Sales and EPS estimates to see what analysts future expectations are.
- ANIXA BIOSCIENCES INC (ANIX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ANIXA BIOSCIENCES INC (ANIX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ANIXA BIOSCIENCES INC (ANIX) Stock Chart to make your own analysis
- ANIXA BIOSCIENCES INC (ANIX) Latest news and press-releases to stay up to date.
Does ANIXA BIOSCIENCES INC (ANIX) stock pay dividends?
ANIX does not pay a dividend.
When does ANIXA BIOSCIENCES INC (ANIX) report earnings?
ANIXA BIOSCIENCES INC (ANIX) will report earnings on 2025-09-04, after the market close.
What is the Price/Earnings (PE) ratio of ANIXA BIOSCIENCES INC (ANIX)?
ANIXA BIOSCIENCES INC (ANIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.38).
What is the Short Interest ratio of ANIXA BIOSCIENCES INC (ANIX) stock?
The outstanding short interest for ANIXA BIOSCIENCES INC (ANIX) is 1.14% of its float. Check the ownership tab for more information on the ANIX short interest.
ANIX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ANIX. When comparing the yearly performance of all stocks, ANIX is one of the better performing stocks in the market, outperforming 91.89% of all stocks.
ANIX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANIX. While ANIX has a great health rating, there are worries on its profitability.
ANIX Financial Highlights
Over the last trailing twelve months ANIX reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS decreased by -2.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.47% | ||
| ROE | -75.52% | ||
| Debt/Equity | 0 |
ANIX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ANIX. The Buy consensus is the average rating of analysts ratings from 9 analysts.